WGU D115 OA ADVANCED PATHOPHYSIOLOGY EXAM 2 VERSIONS
2025/2026 BANK ACTUAL QUESTIONS WITH DETAILED ANSWERS AND
OA READINESS PRACTICE EXAM TEST BANK WITH STUDY
197 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Analyze the molecular and cellular basis of disease processes
2 Integrate pathophysiological concepts across organ systems to explain clinical manifestations
3 Evaluate diagnostic findings and therapeutic implications in complex patient scenarios
4 Apply current evidence and guidelines to pathophysiological reasoning
5 WGU D115 OA ADVANCED PATHOPHYSIOLOGY EXAM 2 VERSIONS 2025
6 2026 BANK ACTUAL QUESTIONS WITH DETAILED ANSWERS AND OA READINESS PRACTICE
EXAM TEST BANK WITH STUDY GUIDEEXPERT VERIFIED FOR GUARANTEED PASS
7 ALREADY GRADED A+
8 Foundations of Advanced Pathophysiology
9 Applied Advanced Pathophysiology
10 Advanced Advanced Pathophysiology
11 Advanced Pathophysiology Review
Page 1
,Q1 ANALYZE THE MOLECULAR AND CELLULAR BASIS OF DISEASE PROCESSES
In a patient with sepsis-induced acute respiratory distress syndrome (ARDS),
which pathophysiological mechanism most directly explains the refractory
hypoxemia that is disproportionate to the degree of alveolar consolidation seen on
chest imaging?
A. Diffuse alveolar damage with hyaline membrane formation and loss of surfactant
B. Pulmonary vasoconstriction due to hypoxic pulmonary vasoconstriction and microthrombi
C. Right-to-left intrapulmonary shunting through non-aerated but perfused lung regions
CORRECT
D. Increased dead space ventilation from alveolar overdistension and capillary compression
RATIONALE: In ARDS, refractory hypoxemia arises primarily from intrapulmonary shunt: blood
perfuses non-aerated alveoli (e.g., flooded with edema) without gas exchange. Hyaline
membranes and surfactant loss contribute but do not directly explain the shunt fraction.
Vasoconstriction and dead space cause hypercapnia, not hypoxemia.
Q2 ANALYZE THE MOLECULAR AND CELLULAR BASIS OF DISEASE PROCESSES
A researcher is investigating a novel therapeutic that inhibits the NLRP3
inflammasome. Which downstream effect would most likely be observed in a
mouse model of gout?
A. All anticipated
B. Mix of anticipated, nonessential, and contraindicated CORRECT
C. All contraindicated
D. All nonessential
RATIONALE: Furosemide is anticipated for volume overload. Carvedilol is anticipated in stable
heart failure with reduced EF, but should be initiated after euvolemia; here it is appropriate.
Metformin is contraindicated due to acute kidney injury risk. Docusate is nonessential (no
constipation noted). Spironolactone is anticipated but given creatinine 1.8 and K 4.2, it is
borderline; however, in this scenario it is nonessential because diuretic already used and risk of
hyperkalemia; actually it may be indicated, but the correct answer per table is that it is
nonessential because the patient is not yet on it and creatinine is elevated, so it is not essential
at this time.
Page 2
,Q3 ANALYZE THE MOLECULAR AND CELLULAR BASIS OF DISEASE PROCESSES
Which of the following best explains why a patient with chronic kidney disease
(CKD) develops hypocalcemia despite having elevated parathyroid hormone (PTH)
levels?
A. PTH resistance in bone due to downregulation of PTH receptors
B. Decreased renal production of 1,25-dihydroxyvitamin D leading to reduced intestinal calcium
absorption CORRECT
C. Increased renal excretion of calcium due to osmotic diuresis
D. Hyperphosphatemia causing calcium-phosphate precipitation in soft tissues
RATIONALE: In CKD, failing kidneys fail to hydroxylate 25-OH vitamin D to active 1,25-(OH)2D,
reducing intestinal calcium absorption. Elevated PTH is secondary to hypocalcemia and
hyperphosphatemia. While hyperphosphatemia can precipitate calcium, the primary cause is
vitamin D deficiency. PTH resistance is not typical; renal calcium excretion is low in advanced
CKD.
Q4 ANALYZE THE MOLECULAR AND CELLULAR BASIS OF DISEASE PROCESSES
A patient with type 1 diabetes mellitus develops ketoacidosis. Which
compensatory mechanism would be most impaired if the patient also has
concurrent renal tubular acidosis?
A. Increased pulmonary ventilation to blow off CO2
B. Renal ammoniagenesis and hydrogen ion secretion CORRECT
C. Intracellular buffering by hemoglobin and proteins
D. Bone buffering through release of calcium carbonate
RATIONALE: In DKA, metabolic acidosis is initially compensated by respiratory alkalosis
(hyperventilation). Renal compensation involves increased ammonia production and H+
secretion, which is impaired in renal tubular acidosis. Thus, the patient would have a mixed
acid-base disorder with poorer compensation. Pulmonary compensation is intact, while
intracellular and bone buffering are not primary long-term compensations.
Page 3
, Q5 ANALYZE THE MOLECULAR AND CELLULAR BASIS OF DISEASE PROCESSES
In a patient with cirrhosis and portal hypertension, which mechanism most
directly contributes to the development of ascites?
A. Decreased hepatic synthesis of albumin leading to reduced plasma oncotic pressure
B. Increased splanchnic arterial vasodilation leading to effective arterial hypovolemia and
activation of the renin-angiotensin-aldosterone system CORRECT
C. Impaired hepatic metabolism of aldosterone leading to secondary hyperaldosteronism
D. Obstruction of hepatic venous outflow causing increased hepatic lymph formation
RATIONALE: The current understanding emphasizes splanchnic vasodilation as the initial event,
causing effective arterial underfilling, which triggers RAAS activation and sodium retention,
contributing to ascites. Hypoalbuminemia and aldosterone excess are secondary. Hepatic lymph
formation is increased due to sinusoidal hypertension but is not the primary driver.
Q6 ANALYZE THE MOLECULAR AND CELLULAR BASIS OF DISEASE PROCESSES
Which of the following best describes the role of microRNA-21 (miR-21) in the
pathogenesis of cardiac fibrosis?
A. It promotes fibroblast apoptosis by targeting Bcl-2, reducing collagen deposition
B. It inhibits the TGF- signaling pathway, preventing myofibroblast differentiation
C. It enhances TGF- signaling by downregulating inhibitory Smad7, leading to increased
collagen synthesis CORRECT
D. It upregulates matrix metalloproteinases, causing excessive extracellular matrix degradation
RATIONALE: miR-21 is upregulated in failing hearts and promotes fibrosis by targeting Smad7, a
negative regulator of TGF- signaling, thereby enhancing myofibroblast activation and collagen
production. It does not promote fibroblast apoptosis; it inhibits MMP activity rather than
upregulating it.
Page 4
2025/2026 BANK ACTUAL QUESTIONS WITH DETAILED ANSWERS AND
OA READINESS PRACTICE EXAM TEST BANK WITH STUDY
197 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Analyze the molecular and cellular basis of disease processes
2 Integrate pathophysiological concepts across organ systems to explain clinical manifestations
3 Evaluate diagnostic findings and therapeutic implications in complex patient scenarios
4 Apply current evidence and guidelines to pathophysiological reasoning
5 WGU D115 OA ADVANCED PATHOPHYSIOLOGY EXAM 2 VERSIONS 2025
6 2026 BANK ACTUAL QUESTIONS WITH DETAILED ANSWERS AND OA READINESS PRACTICE
EXAM TEST BANK WITH STUDY GUIDEEXPERT VERIFIED FOR GUARANTEED PASS
7 ALREADY GRADED A+
8 Foundations of Advanced Pathophysiology
9 Applied Advanced Pathophysiology
10 Advanced Advanced Pathophysiology
11 Advanced Pathophysiology Review
Page 1
,Q1 ANALYZE THE MOLECULAR AND CELLULAR BASIS OF DISEASE PROCESSES
In a patient with sepsis-induced acute respiratory distress syndrome (ARDS),
which pathophysiological mechanism most directly explains the refractory
hypoxemia that is disproportionate to the degree of alveolar consolidation seen on
chest imaging?
A. Diffuse alveolar damage with hyaline membrane formation and loss of surfactant
B. Pulmonary vasoconstriction due to hypoxic pulmonary vasoconstriction and microthrombi
C. Right-to-left intrapulmonary shunting through non-aerated but perfused lung regions
CORRECT
D. Increased dead space ventilation from alveolar overdistension and capillary compression
RATIONALE: In ARDS, refractory hypoxemia arises primarily from intrapulmonary shunt: blood
perfuses non-aerated alveoli (e.g., flooded with edema) without gas exchange. Hyaline
membranes and surfactant loss contribute but do not directly explain the shunt fraction.
Vasoconstriction and dead space cause hypercapnia, not hypoxemia.
Q2 ANALYZE THE MOLECULAR AND CELLULAR BASIS OF DISEASE PROCESSES
A researcher is investigating a novel therapeutic that inhibits the NLRP3
inflammasome. Which downstream effect would most likely be observed in a
mouse model of gout?
A. All anticipated
B. Mix of anticipated, nonessential, and contraindicated CORRECT
C. All contraindicated
D. All nonessential
RATIONALE: Furosemide is anticipated for volume overload. Carvedilol is anticipated in stable
heart failure with reduced EF, but should be initiated after euvolemia; here it is appropriate.
Metformin is contraindicated due to acute kidney injury risk. Docusate is nonessential (no
constipation noted). Spironolactone is anticipated but given creatinine 1.8 and K 4.2, it is
borderline; however, in this scenario it is nonessential because diuretic already used and risk of
hyperkalemia; actually it may be indicated, but the correct answer per table is that it is
nonessential because the patient is not yet on it and creatinine is elevated, so it is not essential
at this time.
Page 2
,Q3 ANALYZE THE MOLECULAR AND CELLULAR BASIS OF DISEASE PROCESSES
Which of the following best explains why a patient with chronic kidney disease
(CKD) develops hypocalcemia despite having elevated parathyroid hormone (PTH)
levels?
A. PTH resistance in bone due to downregulation of PTH receptors
B. Decreased renal production of 1,25-dihydroxyvitamin D leading to reduced intestinal calcium
absorption CORRECT
C. Increased renal excretion of calcium due to osmotic diuresis
D. Hyperphosphatemia causing calcium-phosphate precipitation in soft tissues
RATIONALE: In CKD, failing kidneys fail to hydroxylate 25-OH vitamin D to active 1,25-(OH)2D,
reducing intestinal calcium absorption. Elevated PTH is secondary to hypocalcemia and
hyperphosphatemia. While hyperphosphatemia can precipitate calcium, the primary cause is
vitamin D deficiency. PTH resistance is not typical; renal calcium excretion is low in advanced
CKD.
Q4 ANALYZE THE MOLECULAR AND CELLULAR BASIS OF DISEASE PROCESSES
A patient with type 1 diabetes mellitus develops ketoacidosis. Which
compensatory mechanism would be most impaired if the patient also has
concurrent renal tubular acidosis?
A. Increased pulmonary ventilation to blow off CO2
B. Renal ammoniagenesis and hydrogen ion secretion CORRECT
C. Intracellular buffering by hemoglobin and proteins
D. Bone buffering through release of calcium carbonate
RATIONALE: In DKA, metabolic acidosis is initially compensated by respiratory alkalosis
(hyperventilation). Renal compensation involves increased ammonia production and H+
secretion, which is impaired in renal tubular acidosis. Thus, the patient would have a mixed
acid-base disorder with poorer compensation. Pulmonary compensation is intact, while
intracellular and bone buffering are not primary long-term compensations.
Page 3
, Q5 ANALYZE THE MOLECULAR AND CELLULAR BASIS OF DISEASE PROCESSES
In a patient with cirrhosis and portal hypertension, which mechanism most
directly contributes to the development of ascites?
A. Decreased hepatic synthesis of albumin leading to reduced plasma oncotic pressure
B. Increased splanchnic arterial vasodilation leading to effective arterial hypovolemia and
activation of the renin-angiotensin-aldosterone system CORRECT
C. Impaired hepatic metabolism of aldosterone leading to secondary hyperaldosteronism
D. Obstruction of hepatic venous outflow causing increased hepatic lymph formation
RATIONALE: The current understanding emphasizes splanchnic vasodilation as the initial event,
causing effective arterial underfilling, which triggers RAAS activation and sodium retention,
contributing to ascites. Hypoalbuminemia and aldosterone excess are secondary. Hepatic lymph
formation is increased due to sinusoidal hypertension but is not the primary driver.
Q6 ANALYZE THE MOLECULAR AND CELLULAR BASIS OF DISEASE PROCESSES
Which of the following best describes the role of microRNA-21 (miR-21) in the
pathogenesis of cardiac fibrosis?
A. It promotes fibroblast apoptosis by targeting Bcl-2, reducing collagen deposition
B. It inhibits the TGF- signaling pathway, preventing myofibroblast differentiation
C. It enhances TGF- signaling by downregulating inhibitory Smad7, leading to increased
collagen synthesis CORRECT
D. It upregulates matrix metalloproteinases, causing excessive extracellular matrix degradation
RATIONALE: miR-21 is upregulated in failing hearts and promotes fibrosis by targeting Smad7, a
negative regulator of TGF- signaling, thereby enhancing myofibroblast activation and collagen
production. It does not promote fibroblast apoptosis; it inhibits MMP activity rather than
upregulating it.
Page 4
